SEARCH

SEARCH BY CITATION

References

  • 1
    WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988; 41: 105114.
  • 2
    Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002; 347: 17131716.
  • 3
    Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005; 36: 720723.
  • 4
    Johnston SC, Fayad PB, Gorelick PB, et al. Prevalence and knowledge of transient ischemic attacks among US adults. Neurology 2003; 60: 14241428.
  • 5
    Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency-department diagnosis of transient ischemic attack. JAMA 2000; 284: 29012906.
  • 6
    Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328: 326328.
  • 7
    Daffertshofer M, Mielke O, Pullwitt A, et al. Transient ischemic attacks are more than “ministrokes”. Stroke 2004; 35: 24532458.
  • 8
    Hill MD, Yiannakoulias N, Jeerakathil T, et al. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004; 62: 20152020.
  • 9
    Goldstein LB, Bian J, Samsa GP, et al. New transient ischemic attack and stroke: outpatient management by primary care physicians. Arch Intern Med 2000; 160: 29412946.
  • 10
    Johnston SC, Smith WS. Practice variability in management of transient ischemic attacks. Eur Neurol 1999; 42: 105108.
  • 11
    Deutsch SC, Denton M, Borenstein J. Clinical practice guidelines: a tool to help provide quality care. Geriatrics 1998; 53: 5473.
  • 12
    Ray-Coquard I, Philip T, Lehmann M, et al. Impact of a clinical guidelines program for breast and colon cancer in a French cancer center. JAMA 1997; 278: 15911595.
  • 13
    Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005; 46: 12421248.
  • 14
    Hart RG, Bailey RD. An assessment of guidelines for prevention of ischemic stroke. Neurology 2002; 59: 977982.
  • 15
    Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281: 19001905.
  • 16
    McAlister FA, Campbell NR, Zarnke K, et al. The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. CMAJ 2001; 164: 517522.
  • 17
    Normand SL, McNeil BJ, Peterson LE, Palmer RH. Eliciting expert opinion using the Delphi technique: identifying performance indicators for cardiovascular disease. Int J Qual Health Care 1998; 10: 247260.
  • 18
    The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines. Qual Saf Health Care 2003; 12: 1823.
  • 19
    Institute for Clinical Systems Improvement. Diagnosis and initial treatment of ischemic stroke. Bloomington, MN: Institute for Clinical Systems Improvement, 2005: 63.
  • 20
    Stroke Prevention and Educational Awareness Diffusion. Italian guidelines for stroke prevention and management: syntheses and recommendations. Milan, Italy: Stroke Prevention and Educational Awareness Diffusion, 2003: 38.
  • 21
    Scottish Intercollegiate Guidelines Network. Management of patients with stroke. I: Assessment, investigation, immediate management and secondary prevention. National clinical guideline. Edinburgh, United Kingdom: Scottish Intercollegiate Guidelines Network, 1997: 32.
  • 22
    Royal College of Physicians Intercollegiate Stroke Working Party. National clinical guidelines for stroke. 2nd ed. London: Royal College of Physicians, 2004: 134.
  • 23
    Singapore Ministry of Health. Stroke and transient ischaemic attacks: assessment, investigation, immediate management and secondary prevention. Clinical practice guidelines. Singapore: Singapore Ministry of Health, 2003: 38.
  • 24
    Culebras A, Kase CS, Masdeu JC, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke. A report of the Stroke Council, American Heart Association. Stroke 1997; 28: 14801497.
  • 25
    New Zealand Guidelines Group. Evidence-based best practice guideline: the assessment and management of cardiovascular risk. Wellington, New Zealand: New Zealand Guidelines Group, 2003: 190.
  • 26
    Albers GW, Hart RG, Lutsep HL, et al. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999; 30: 25022511.
  • 27
    Leys D, Kwiecinski H, Bogousslavsky J, et al. Prevention. European Stroke Initiative. Cerebrovasc Dis 2004; 17(suppl 2): 1529.
  • 28
    Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483S512S.
  • 29
    Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1998; 97: 501509.
  • 30
    Sowerby Centre for Health Informatics at Newcastle. PRODIGY guidance: atrial fibrillation. Vol. 2005. Newcastle, United Kingdom: Sowerby Centre for Health Informatics at Newcastle, 2004
  • 31
    Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. BMJ 1998; 316: 13031309.
  • 32
    Rothwell PM, Buchan A, Johnston SC. Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. Lancet Neurol 2006; 5: 323331.
  • 33
    Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493498.
  • 34
    Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577617.
  • 35
    Sowerby Centre for Health Informatics at Newcastle. PRODIGY guidance: atrial fibrillation. Vol. 2006. Newcastle, United Kingdom: Sowerby Centre for Health Informatics at Newcastle, 2005
  • 36
    Institute for Clinical Systems Improvement. Diagnosis and initial treatment of ischemic stroke. Bloomington, MN: Institute for Clinical Systems Improvement, 2006: 63.
  • 37
    Stroke Prevention and Educational Awareness Diffusion. Italian guidelines for stroke prevention and management: syntheses and recommendations. Milan, Italy: Stroke Prevention and Educational Awareness Diffusion, 2005: 38.
  • 38
    Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 2005; 366: 2936.
  • 39
    Blight A, Pereira AC, Brown MM. A single consultation cerebrovascular disease clinic is cost effective in the management of transient ischaemic attack and minor stroke. J R Coll Physicians Lond 2000; 34: 452455.
  • 40
    Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 2000; 283: 31023109.
  • 41
    Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915924.
  • 42
    Robless P, Baxter A, Byrd S, et al. The prevalence of cerebral infarcts in the Asymptomatic Carotid Surgery Trial (ACST) in relation to prior contralateral symptoms. Int Angiol 1998; 17: 187193.
  • 43
    Patel SG, Collie DA, Wardlaw JM, et al. Outcome, observer reliability, and patient preferences if CTA, MRA, or Doppler ultrasound were used, individually or together, instead of digital subtraction angiography before carotid endarterectomy. J Neurol Neurosurg Psychiatry 2002; 73: 2128.
  • 44
    Deriu GP, Milite D, Damiani N, et al. Carotid endarterectomy without angiography: a prospective randomised pilot study. Eur J Vasc Endovasc Surg 2000; 20: 250253.
  • 45
    Lewis RF, Abrahamowicz M, Cote R, Battista RN. Predictive power of duplex ultrasonography in asymptomatic carotid disease. Ann Intern Med 1997; 127: 1320.
  • 46
    Nederkoorn PJ, Mali WP, Eikelboom BC, et al. Preoperative diagnosis of carotid artery stenosis: accuracy of noninvasive testing. Stroke 2002; 33: 20032008.
  • 47
    Henderson RD, Eliasziw M, Fox AJ, et al. Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Stroke 2000; 31: 128132.
  • 48
    Kapral MK, Silver FL. Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. CMAJ 1999; 161: 989996.
  • 49
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 7186.
  • 50
    The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857865.
  • 51
    Sandercock P, Mielke O, Liu M, Counsell C. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2003: CD000248.
  • 52
    The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 510.
  • 53
    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 13051316.
  • 54
    Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 2004; 35: 948951.
  • 55
    Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817821.
  • 56
    Saxena R, Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004: CD000187.
  • 57
    Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 22872292.
  • 58
    Algra A, De Schryver EL, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. Stroke 2003; 34: 234235.
  • 59
    van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 24412448.
  • 60
    Cohen A, Tzourio C, Chauvel C, et al. Mitral valve strands and the risk of ischemic stroke in elderly patients. The French Study of Aortic Plaques in Stroke (FAPS) Investigators. Stroke 1997; 28: 15741578.
  • 61
    Gilon D, Buonanno FS, Joffe MM, et al. Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med 1999; 341: 813.
  • 62
    Orencia AJ, Petty GW, Khandheria BK, et al. Mitral valve prolapse and the risk of stroke after initial cerebral ischemia. Neurology 1995; 45: 10831086.
  • 63
    Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341: 17.
  • 64
    Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687691.
  • 65
    Gorter JW, Algra A, van Gijn J, et al. SPIRIT: predictors of anticoagulant-related bleeding complications in patients after cerebral ischemia. Cerebrovasc Dis 1997; 7: 3 (Abstract).
  • 66
    Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999; 53: 13191327.
  • 67
    The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003; 34: e45e46.
  • 68
    Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 14441451.
  • 69
    EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 12551262.
  • 70
    Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S589S.
  • 71
    Petty GW, Orencia AJ, Khandheria BK, Whisnant JP. A population-based study of stroke in the setting of mitral valve prolapse: risk factors and infarct subtype classification. Mayo Clin Proc 1994; 69: 632634.
  • 72
    Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540546.
  • 73
    Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633638.
  • 74
    Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156: 23112316.
  • 75
    Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445S469S.
  • 76
    Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 2003; 254: 95101.
  • 77
    Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 17401746.
  • 78
    Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 16821687.
  • 79
    Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 21792184.
  • 80
    Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361: 107116.
  • 81
    Rothwell PM, Mehta Z, Howard SC, et al. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005; 365: 256265.
  • 82
    Gasecki AP, Eliasziw M, Ferguson GG, et al. Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. J Neurosurg 1995; 83: 778782.
  • 83
    Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47: 12551256.
  • 84
    Kirshner HS, Biller J, Callahan AS 3rd. Long-term therapy to prevent stroke. J Am Board Fam Pract 2005; 18: 528540.
  • 85
    Love BB, Grover-McKay M, Biller J, et al. Coronary artery disease and cardiac events with asymptomatic and symptomatic cerebrovascular disease. Stroke 1992; 23: 939945.
  • 86
    Eliasziw M, Kennedy J, Hill MD, et al. Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. CMAJ 2004; 170: 11051109.
  • 87
    Di Pasquale G, Andreoli A, Pinelli G, et al. Cerebral ischemia and asymptomatic coronary artery disease: a prospective study of 83 patients. Stroke 1986; 17: 10981101.
  • 88
    Di Pasquale G, Pinelli G, Grazi P, et al. Incidence of silent myocardial ischaemia in patients with cerebral ischaemia. Eur Heart J 1988; 9 (suppl N): 104–107.
  • 89
    Gates P, Peppard R, Kempster P, et al. Clinically unsuspected cardiac disease in patients with cerebral ischaemia. Clin Exp Neurol 1987; 23: 7580.
  • 90
    Gates PC, Eliasziw M, Algra A, et al. Identifying patients with symptomatic carotid artery disease at high and low risk of severe myocardial infarction and cardiac death. Stroke 2002; 33: 24132416.
  • 91
    Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33: 901906.
  • 92
    Dexter DD Jr, Whisnant JP, Connolly DC, O'Fallon WM. The association of stroke and coronary heart disease: a population study. Mayo Clin Proc 1987; 62: 10771083.
  • 93
    Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham study. Stroke 1982; 13: 290295.
  • 94
    Heyman A, Wilkinson WE, Hurwitz BJ, et al. Risk of ischemic heart disease in patients with TIA. Neurology 1984; 34: 626630.
  • 95
    Rokey R, Rolak LA, Harati Y, et al. Coronary artery disease in patients with cerebrovascular disease: a prospective study. Ann Neurol 1984; 16: 5053.
  • 96
    Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003; 163: 669676.
  • 97
    Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757767.
  • 98
    The Stroke Council. Statins after ischemic stroke and transient ischemic attack. Stroke 2004; 35: 1023.
  • 99
    Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434444.
  • 100
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 101
    Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med 2005; 165: 21142120.
  • 102
    Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005; 99: 11931204.
  • 103
    Berthet K, Neal BC, Chalmers JP, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004; 13: 713.
  • 104
    Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 26432653.
  • 105
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 9951003.
  • 106
    HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253259.
  • 107
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 29812997.
  • 108
    Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 19671975.
  • 109
    Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 12181226.
  • 110
    Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 16991703.
  • 111
    Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005; 36: 21642169.
  • 112
    Hilleman DE, Lucas BD Jr. Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction? Pharmacotherapy 2004; 24: 10641076.
  • 113
    Fukui T, Rahman M, Hayashi K, et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979990.
  • 114
    Progress Management Committee. PROGRESS—Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999; 17: 16471655.
  • 115
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 25602572.
  • 116
    Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005: CD001292.
  • 117
    Kernan WN, Viscoli CM, Brass LM, et al. Decline in physical performance among women with a recent transient ischemic attack or ischemic stroke: opportunities for functional preservation a report of the Women's Estrogen Stroke Trial. Stroke 2005; 36: 630634.
  • 118
    Lee IM, Hennekens CH, Berger K, et al. Exercise and risk of stroke in male physicians. Stroke 1999; 30: 16.